UPDATE - Canaccord Genuity Initiates Coverage on MAP Pharmaceuticals (MAPP) with a Buy; Top Small-Cap Catalyst-Driven Idea
MAPP Hot Sheet
Rating Summary:3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
UPDATE - Canaccord Genuity initiates coverage on MAP Pharmaceuticals (NASDAQ: MAPP) with a Buy. PT $24.00.
Canaccord analyst, Randall Stanicky, said, "Shares trade well below our NPV estimate for lead migraine drug LEVADEX, reflective of a risk-off environment that has left several small-cap and catalyst-driven names overlooked. MAPP fits that bill and we would be BUYERS into the March 26, 2012 PDUFA. We think approval is likely and see MAPP as a small-cap
way to play the under-served migraine market with leverage to partner Allergan (which will co-promote LEVADEX for acute migraine alongside recently approved Botox for chronic migraine). Several other events are lined up, setting the stage for a catalyst-heavy H1/12. This is our top small-cap idea, with our $24 target reflecting more than 70% upside potential."
To see more ratings on MAPP, Click Here
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
Canaccord analyst, Randall Stanicky, said, "Shares trade well below our NPV estimate for lead migraine drug LEVADEX, reflective of a risk-off environment that has left several small-cap and catalyst-driven names overlooked. MAPP fits that bill and we would be BUYERS into the March 26, 2012 PDUFA. We think approval is likely and see MAPP as a small-cap
way to play the under-served migraine market with leverage to partner Allergan (which will co-promote LEVADEX for acute migraine alongside recently approved Botox for chronic migraine). Several other events are lined up, setting the stage for a catalyst-heavy H1/12. This is our top small-cap idea, with our $24 target reflecting more than 70% upside potential."
To see more ratings on MAPP, Click Here
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Wunderlich Securities Starts Fastenal (FAST) at Buy
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
Create E-mail Alert Related Categories
New CoverageRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
